Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "Biopharmaceutical"

638 News Found

Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial
Clinical Trials | November 21, 2025

Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial

Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration


Evonik and InVitria form strategic partnership to supply animal-free albumin to global biopharma market
News | November 18, 2025

Evonik and InVitria form strategic partnership to supply animal-free albumin to global biopharma market

Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers


Galmed’s Aramchol shows promise in overcoming gastrointestinal cancer drug resistance
Clinical Trials | November 18, 2025

Galmed’s Aramchol shows promise in overcoming gastrointestinal cancer drug resistance

Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma


AstraZeneca and Sun Pharma partner to expand hyperkalemia treatment in India
News | November 17, 2025

AstraZeneca and Sun Pharma partner to expand hyperkalemia treatment in India

Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names


Pfizer completes up to $10 billion acquisition of Metsera
News | November 14, 2025

Pfizer completes up to $10 billion acquisition of Metsera

Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape


SpyGlass Pharma reports promising clinical trial results for glaucoma therapy
Biopharma | November 14, 2025

SpyGlass Pharma reports promising clinical trial results for glaucoma therapy

The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance


AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial
Clinical Trials | November 12, 2025

AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial

Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo


AstraZeneca delivers double-digit growth
News | November 10, 2025

AstraZeneca delivers double-digit growth

The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy


Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'
Drug Approval | November 10, 2025

Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'

The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases